Public procurement of medicines: scoping review of the scientific literature in South America

References

• ONU Nações Unidas no Brasil. Transformando Nosso Mundo: A Agenda 2030 para o Desenvolvimento Sustentável [Internet]. ONU Brasil. 2015 [citado 16 de outubro de 2018]. Disponível em: https://nacoesunidas.org/pos2015/agenda2030/
   Google Scholar
• OPS - Organización PanAmericana de la Salud. Salud Universal [Internet]. [citado 16 de outubro de 2018]. Disponível em: https://www.paho.org/hq/index.php?option=com_topics&view=article&id=403&Itemid=40987&lang=es
   Google Scholar
• Mendes LV, Campos MR, Chaves GC, da Silva RM, Freitas P d S, Costa KS, et al. Availability of medicines in primary health care facilities and related factors: a cross sectional approach. Saúde Em Debate. 2014;38.
   Google Scholar
• Instituto Brasileiro de Geografia e Estatística, organizador. Conta-satélite de saúde: Brasil, 2010–2015. Rio de Janeiro: IBGE; 2017. 71 p.
   Google Scholar
• Barcelo A, Arredondo A, Gordillo–Tobar A, Segovia J, Qiang A. The cost of diabetes in Latin America and the Caribbean in 2015: evidence for decision and policy makers. J Glob Health. 2017;7:2.
   Web of Science ®Google Scholar
• Ribeiro CG. Mensurando o mercado de compras governamentais brasileiro. Cad Finanç Públicas.2014;14:23.
   Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol fevereiro de.2005;8(1):19–32.
   Google Scholar
• Osorio-de-Castro CGS, Crisante M, Miranda ES, Oliveira EA, Oliveira MA. Proposed methodology for monitoring antiretroviral drugs price negotiations in Latin America and the Caribbean. Rev Panam Salud Pública. 2009;26(2):137–147.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Organizador. Methods for the economic evaluation of health care programmes. 3. Ed., reprint. Oxford: Oxford Univ. Press; 2007. 379 p.
   Google Scholar
• do ASMS, Blatt CR. Municipal consortia for medicine procurement: impact on the stockout and budget. Rev Saúde Pública. 2011;45(4):799–801.
   PubMed Web of Science ®Google Scholar
• Ferraes AMB, Cordoni Junior L. Consórcio de medicamentos no Paraná: análise de cobertura e custos. Rev Adm Pública junho de.2007;41(3):475–486
   Google Scholar
• da Silva RM, Caetano R. Costs of public pharmaceutical services in Rio de Janeiro compared to Farmácia popular program. Rev Saude Publica. 2016;50.
   Google Scholar
• Wang DWL, de VNP, de OVE, Terrazas FV. The impacts of health care judicialization in the city of Sao Paulo: public expenditure and federal organization. Rev Adm Pública.2014;48(5):1191–1206.
   Google Scholar
• Botta CA. Evaluación del suministro de medicamentos en los servicios de atención primaria de salud de Rosario, Argentina, 2005. Rev Panam Salud Pública.2009;25(4):283–291.
   PubMedGoogle Scholar
• Garcia MM, Guerra Júnior AA, Acúrcio F de A. Economic evaluation of the programs Rede Farmácia de Minas do SUS versus Farmácia popular do Brasil. Ciênc Saúde Coletiva.2017;22(1):221–233.
   PubMed Web of Science ®Google Scholar
• Seoane-Vazquez E, Rodriguez-Monguio R. Access to essential drugs in Guyana: a public health challenge. Int J Health Plann Manag.2010;25(1):2–16.
   PubMed Web of Science ®Google Scholar
• da Silva RM, Pereira NC, Mendes LVP, Luiza VL. Pharmaceutical services in Rio de Janeiro municipality, Brazil: development regarding selected aspects from 2008 to 2014. Cienc E Saude Coletiva. 2016;21(5):1421–1432.
   PubMed Web of Science ®Google Scholar
• da Silva RM, Caetano R. Expenditures on medicines by the Rio de Janeiro municipal health department, Brazil, 2002-2011. Cad Saude Publica. 2014;30(6):1207–1218.
   PubMed Web of Science ®Google Scholar
• Luo J, Osorio-De-Castro C, Olivera M, Ramos M, Maia A. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011. J Gen Intern Med.2014;29:S25.
   PubMed Web of Science ®Google Scholar
• Costa RD, Osorio-De-Castro CG, Silva RM, Maia AA, Ramos MC, Caetano R. An analysis of medicine procurement for Alzheimer’s disease in Brazil from federal purchases. Ciênc Saúde Coletiva. 2015;20(12):3827–3838.
   PubMed Web of Science ®Google Scholar
• Moraes EL, Osorio-de-Castro CGS, Caetano R. Federal procurement of antineoplastic drugs in Brazil: analysis of imatinib mesylate, trastuzumab and L-asparaginase, 2004-2013. Physis. 2016;26(4):1357–1382.
   Google Scholar
• Nunn AS, Fonseca EM, Bastos FI, Gruskin S, Salomon JA. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med.2007;4(11):1804–1817.
   Web of Science ®Google Scholar
• Meiners Constance, Sagaon-Teyssier Luis, Hasenclever Lia, Moatti Jean-Paul. Modeling HIV/AIDS Drug Price Determinants in Brazil: Is Generic Competition a Myth? PLoS ONE.2011;6(8):e23478.
   PubMed Web of Science ®Google Scholar
• Vieira FS, Zucchi P. Resource allocation for pharmaceutical procurement in the brazilian unified health system. Rev Saude Publica.2011;45(5):906–913.
   PubMed Web of Science ®Google Scholar
• Teodoro CRDS, Caetano R, Godman B, dos Reis ALA, Maia ADA, Ramos MDCB, et al. Federal procurement of unlicensed medicines in Brazil; findings and implications. Expert Rev Pharmacoecon Outcomes Res.2017;17(6):607–613.
   PubMed Web of Science ®Google Scholar
• Raventós P, Zolezzi S. Electronic tendering of pharmaceuticals and medical devices in Chile. J Bus Res.2015;68(12):2569–2578.
   Web of Science ®Google Scholar
• Akku S, Garg A, Khandarkar S. Cost-minimization analysis of generic equivalents (bortezomib, decitabine and capecitabine) in comparison to the originator brand medicines in Colombia. GaBI J.2016;5(4):164–167
   Google Scholar
• Vieira FS, Zucchi P. Financing of Pharmaceutical Services in Brazilian Public Health System. Saúde E Soc.2013;22(1):73–84
   Google Scholar
• Vieira FS. Ministry of Health’s spending on drugs: program trends from 2002 to 2007. Rev Saúde Pública.2009;43(4):674–681.
   PubMed Web of Science ®Google Scholar
• da Fonseca EM, Costa NR. Federalism, the economic-industrial health care complex and high-cost pharmaceutical assistance in Brazil. Cienc E Saude Coletiva.2015;20(4):1165–1176
   PubMed Web of Science ®Google Scholar
• Armijos L, Escalante S, Villacrés T. Health technology assessment in Ecuador’s ministry of public health as a tool for drug purchasing from 2012 to 2015. Rev Panam Salud Publica Pan Am J Public Health. 2017;41.
   Google Scholar
• Luz TCB, Osorio-De-Castro CGS, Magarinos-Torres R, Wettermark B. Trends in medicines procurement by the Brazilian federal government from 2006 to 2013. PLoS One. 2017;12(4).
   Google Scholar
• Magarinos-Torres R, Lynd LD, Luz TCB, Marques PEPC, Osorio-de-Castro CGS. Essential medicines list implementation dynamics: a case study using Brazilian Federal Medicines Expenditures. Basic Clin Pharmacol Toxicol.2017;121(3):181–188.
   PubMed Web of Science ®Google Scholar
• Grangeiro A, Teixeira L, Bastos FI, Teixeira P. Sustentabilidade da política de acesso a medicamentos anti-retrovirais no Brasil. Rev Saúde Pública. 2006;40:60–69.
   PubMed Web of Science ®Google Scholar
• Chaves GC, Hasenclever L, Osorio-de-Castro CGS, Oliveira MA. Strategies for price reduction of HIV medicines under a monopoly situation in Brazil. Rev Saude Publica. 2015;49.
   Google Scholar
• Scopel CT, Chaves GC. Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian unified national health system. Cad Saude Publica.2016;32:11.
   Web of Science ®Google Scholar
• Chaves GC, Serpa Osorio-de-Castro CG, Oliveira MA. Moulin de Vasconcelos DM. Public procurement of hepatitis C medicines in Brazil from 2005 to 2015. Cienc Saude Coletiva.2017;22(9):3129.
   PubMed Web of Science ®Google Scholar
• Mendis S, Fukino K, Cameron A, Laing R, Filipe AJ, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ.2007;85(4):279–288.
   PubMed Web of Science ®Google Scholar
• van Mourik MSM, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord.2010;10:25.
   PubMed Web of Science ®Google Scholar
• Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Dennis R-D. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica.2010;27(4):291–299.
   PubMed Web of Science ®Google Scholar
• Santos Pinto CB, Miranda ES, Martins Emmerick IC, do Rosário Costa N, de Castro CGSO. Medicine prices and availability in the Brazilian popular pharmacy program. Rev Saude Publica.2010;44(4):611–619.
   PubMed Web of Science ®Google Scholar
• Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet Lond Engl.2009;373(9659):240–249.
   PubMed Web of Science ®Google Scholar
• Cameron A, Bansal A, Dua T, Hill SR, Moshe SL, Mantel-Teeuwisse AK, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia. 2012;53(6):962–969.
   PubMed Web of Science ®Google Scholar
• Babar Z-U-D, Lessing C, Mace C, Bissell K. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries. PharmacoEconomics. 2013;31(11):1063–1082.
   PubMed Web of Science ®Google Scholar
• Vasan A, Hoos D, Mukherjee JS, Farmer PE, Rosenfield AG, Perriens JH. The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund. Bull World Health Organ.2006;84(5):393–398.
   PubMed Web of Science ®Google Scholar
• Seoane-Vazquez E, Rodriguez-Monguio R. Negotiating antiretroviral drug prices: the experience of the Andean countries. Health Policy Plan.2007;22(2):63–72.
   PubMed Web of Science ®Google Scholar
• de L Horst MML, Soler O. The PAHO strategic fund: a mechanism to facilitate access to medicines. Rev Panam Salud Publica Pan Am J Public Health.2010;27(1):43–48
   PubMed Web of Science ®Google Scholar
• Marín GH, Polach MA. Costly drugs: analysis and proposals for the Mercosur countries. Rev Panam Salud Publica.2011;30(2):167–176.
   PubMed Web of Science ®Google Scholar
• Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions? Soc Sci Med 1982. 2012;75(9):1572–1580.
   Google Scholar
• Kohler JC, Mitsakakis N, Saadat F, Byng D, Martinez MG. Proofs for PLOS ONE paper: does pharmaceutical pricing transparency matter? Examining Brazil’s public procurement system. Glob Health.2015;11:1.
   PubMed Web of Science ®Google Scholar